A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Trial details
- Registry ID
- NCT06246110
- Phase
- Phase 2
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Alimta; Pemfexy
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110 | Eikon Therapeutics | Phase 2 | Active not recruiting | 2026-12Estimated |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaNCT05456256 | LTRN | Phase 2 | Recruiting | 2026-12Estimated |
| Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerNCT04736173 | RCUS | Phase 2 | Active not recruiting | 2027-05Estimated |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 | IOVA | Phase 2 | Terminated | 2026-02-20Actual |
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |